Quest Diagnostics to Acquire Celera

Quest Diagnostics Incorporated DGX, the world's leading provider of diagnostic testing, information and services, and Celera Corporation CRA, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.